While Spyre Therapeutics Inc. has underperformed by -1.58%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SYRE rose by 170.83%, with highs and lows ranging from $47.97 to $8.43, whereas the simple moving average jumped by 10.66% in the last 200 days.
On September 04, 2024, Wedbush started tracking Spyre Therapeutics Inc. (NASDAQ: SYRE) recommending Outperform. A report published by Evercore ISI on July 16, 2024, Initiated its previous ‘Outperform’ rating for SYRE. Robert W. Baird also rated SYRE shares as ‘Outperform’, setting a target price of $50 on the company’s shares in an initiating report dated May 02, 2024. Wells Fargo March 01, 2024d the rating to Overweight on March 01, 2024, and set its price target from $12 to $35. BTIG Research initiated its ‘Buy’ rating for SYRE, as published in its report on December 20, 2023. Jefferies’s report from December 11, 2023 suggests a price prediction of $31 for SYRE shares, giving the stock a ‘Buy’ rating. Guggenheim also rated the stock as ‘Buy’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Spyre Therapeutics Inc. (SYRE)
Further, the quarter-over-quarter decrease in sales is -100.00%, showing a negative trend in the upcoming months.
One of the most important indicators of Spyre Therapeutics Inc.’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -222.71% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 19.70, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and SYRE is recording 475.66K average volume. On a monthly basis, the volatility of the stock is set at 5.93%, whereas on a weekly basis, it is put at 5.79%, with a gain of 3.83% over the past seven days. Furthermore, long-term investors anticipate a median target price of $45.75, showing growth from the present price of $33.61, which can serve as yet another indication of whether SYRE is worth investing in or should be passed over.
How Do You Analyze Spyre Therapeutics Inc. Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 10.86%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 92.41% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
SYRE shares are owned by institutional investors to the tune of 92.41% at present.
